F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Molecular Cell - United States
doi 10.1016/j.molcel.2018.12.019
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

Clinical Cancer Research
Cancer ResearchOncology
2013English

N6-Methylation of Adenosine (M6A) of FZD10 mRNA Contributes to PARP Inhibitor Resistance

Cancer Research
Cancer ResearchOncology
2019English

RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance

Journal of Clinical Investigation
Medicine
2016English

Maintenance PARP Inhibitor Therapy: Is Maintaining Quality of Life Enough?

The Lancet Oncology
Oncology
2018English

Resistance to a Protein Farnesyltransferase Inhibitor inPlasmodium Falciparum

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2005English

Structure of a Conserved Dimerization Domain Within the F-Box Protein Fbxo7 and the PI31 Proteasome Inhibitor

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2008English

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated With PARP Inhibitor Resistance

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

A Unique Subset of Epithelial Ovarian Cancers With Platinum Sensitivity and PARP Inhibitor Resistance

Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy